Suppr超能文献

相似文献

1
Reference Tissue-Based Kinetic Evaluation of 18F-AV-1451 for Tau Imaging.
J Nucl Med. 2017 Feb;58(2):332-338. doi: 10.2967/jnumed.116.175273. Epub 2016 Sep 1.
2
Kinetic Modeling of the Tau PET Tracer F-AV-1451 in Human Healthy Volunteers and Alzheimer Disease Subjects.
J Nucl Med. 2017 Jul;58(7):1124-1131. doi: 10.2967/jnumed.116.182881. Epub 2016 Dec 1.
3
Tracer Kinetic Analysis of (S)-¹⁸F-THK5117 as a PET Tracer for Assessing Tau Pathology.
J Nucl Med. 2016 Apr;57(4):574-81. doi: 10.2967/jnumed.115.158519. Epub 2016 Jan 21.
4
Pharmacokinetic Evaluation of the Tau PET Radiotracer F-T807 (F-AV-1451) in Human Subjects.
J Nucl Med. 2017 Mar;58(3):484-491. doi: 10.2967/jnumed.115.170910. Epub 2016 Sep 22.
5
In Vivo Comparison of Tau Radioligands F-THK-5351 and F-THK-5317.
J Nucl Med. 2017 Jun;58(6):996-1002. doi: 10.2967/jnumed.116.182980. Epub 2016 Nov 10.
6
Modeling Strategies for Quantification of In Vivo F-AV-1451 Binding in Patients with Tau Pathology.
J Nucl Med. 2017 Apr;58(4):623-631. doi: 10.2967/jnumed.116.174508. Epub 2016 Oct 20.
7
Spatially constrained kinetic modeling with dual reference tissues improves F-flortaucipir PET in studies of Alzheimer disease.
Eur J Nucl Med Mol Imaging. 2021 Sep;48(10):3172-3186. doi: 10.1007/s00259-020-05134-w. Epub 2021 Feb 18.

引用本文的文献

1
Plasma p-tau217 predicting brain-wide tau accumulation in preclinical AD.
J Prev Alzheimers Dis. 2025 Jun 20:100252. doi: 10.1016/j.tjpad.2025.100252.
2
Tau Imaging: Use and Implementation in New Diagnostic and Therapeutic Paradigms for Alzheimer's Disease.
Geriatrics (Basel). 2025 Feb 14;10(1):27. doi: 10.3390/geriatrics10010027.
3
Cognitive aging outcomes are related to both tau pathology and maintenance of cingulate cortex structure.
Alzheimers Dement. 2025 Feb;21(2):e14515. doi: 10.1002/alz.14515. Epub 2025 Jan 14.
4
Overview of Alzheimer's Disease Neuroimaging Initiative and future clinical trials.
Alzheimers Dement. 2025 Jan;21(1):e14321. doi: 10.1002/alz.14321. Epub 2024 Dec 22.
6
Tau accumulation and atrophy predict amyloid independent cognitive decline in aging.
Alzheimers Dement. 2024 Apr;20(4):2526-2537. doi: 10.1002/alz.13654. Epub 2024 Feb 9.
7
A review of the flortaucipir literature for positron emission tomography imaging of tau neurofibrillary tangles.
Brain Commun. 2023 Nov 16;6(1):fcad305. doi: 10.1093/braincomms/fcad305. eCollection 2024.

本文引用的文献

2
18F-THK5351: A Novel PET Radiotracer for Imaging Neurofibrillary Pathology in Alzheimer Disease.
J Nucl Med. 2016 Feb;57(2):208-14. doi: 10.2967/jnumed.115.164848. Epub 2015 Nov 5.
3
Tau positron emission tomographic imaging in aging and early Alzheimer disease.
Ann Neurol. 2016 Jan;79(1):110-9. doi: 10.1002/ana.24546. Epub 2015 Dec 15.
4
Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue.
Ann Neurol. 2015 Nov;78(5):787-800. doi: 10.1002/ana.24517. Epub 2015 Sep 25.
5
Tau imaging: early progress and future directions.
Lancet Neurol. 2015 Jan;14(1):114-24. doi: 10.1016/S1474-4422(14)70252-2.
6
The simplified reference tissue model: model assumption violations and their impact on binding potential.
J Cereb Blood Flow Metab. 2015 Feb;35(2):304-11. doi: 10.1038/jcbfm.2014.202. Epub 2014 Nov 26.
7
Primary age-related tauopathy (PART): a common pathology associated with human aging.
Acta Neuropathol. 2014 Dec;128(6):755-66. doi: 10.1007/s00401-014-1349-0. Epub 2014 Oct 28.
8
Tau PET imaging in Alzheimer's disease.
Curr Neurol Neurosci Rep. 2014 Nov;14(11):500. doi: 10.1007/s11910-014-0500-6.
9
Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET.
Brain. 2014 Jun;137(Pt 6):1762-71. doi: 10.1093/brain/awu064. Epub 2014 Mar 27.
10
Assessing THK523 selectivity for tau deposits in Alzheimer's disease and non-Alzheimer's disease tauopathies.
Alzheimers Res Ther. 2014 Feb 26;6(1):11. doi: 10.1186/alzrt240. eCollection 2014.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验